Por: MarketWatch Business October 09, 2023
Alnylam said in a Monday morning that the FDA had not been satisfied by the clinical meaningfulness of the drug’s efficacy. An approval in the cardiomyopathy indication could have meant a significant boost to Alnylam sales, which were $1 billion in 2022. Far more patients suffer from ATTR with cardiomyopathy than with polyneuropathy, though questions about Onpattro’s efficacy in the indication have dogged the program, and analysts had muted... + full article
RTTNews USA Health September 13, 2023
Alnylam Pharmaceuticals, Inc. () said NASDAQ has halted trading of the company's common stock on Wednesday as the FDA Cardiovascular and Renal Drugs Advisory Committee is meeting to review the supplemental New Drug Application for patisiran, an investigational RNAi... + más
Alnylam signs $2.8 billion deal with Roche to advance Cambridge biotech’s injection for high blood pressure | The Boston Globe
Alnylam’s experimental Alzheimer’s drug shows benefits in patients for six months | The Boston Globe
The Boston Globe USA Business July 24, 2023
Roche Holding AG will work together with Alnylam Pharmaceuticals Inc. on a potential treatment for high blood pressure in a deal worth as much as $2.8 billion, expanding the Swiss company’s footprint beyond the cancer therapies that long anchored its business.Roche will pay... + más
Alnylam Pharmaceuticals will receive $310 million in cash from the Swiss drug giant Roche Holding AG and be eligible for as much as $2.5 billion more in a deal to jointly develop and market the Cambridge biotech’s novel potential treatment for high blood pressure.The firms... + más
Alnylam halts work on eye drug, citing new US law over pricing | The Boston Globe
The Boston Globe USA Business July 17, 2023
Alzheimer’s patients who received a single dose of an experimental gene-silencing treatment from Alnylam Pharmaceuticals showed benefits for six months in a small study, the Cambridge biotech said Monday.Alnylam reported in April that recipients of the medicine experienced... + más
Alnylam deploys gene-silencing in early study aimed at subduing Alzheimer’s | The Boston Globe
The Boston Globe USA Business April 26, 2023
Cambridge scientists are deploying a novel gene-silencing technology used against ultra-rare diseases in a new effort to subdue Alzheimer’s, the memory-raving disorder that afflicts tens of millions of people worldwide.In findings reported Wednesday afternoon, Alnylam... + más
Reimagining Alzheimer’s (Part 8): APOE4 Removal Reduces Symptoms Of Alzheimer’s Disease | Forbes
RTTNews USA Health October 28, 2022
The following are some of the companies belonging to the healthcare sector that reported quarterly financial results on Thursday.Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY), which reported lower-than-expected financial results for the third quarter, has reiterated FY 2022 net... + más
Help Wanted: Treasury And The IRS Gear Up On Energy Tax Guidance | Forbes
Health Care — Trump staffers interfered in CDC guidance, report finds | The Hill
The Boston Globe USA Business October 27, 2022
Alnylam Pharmaceuticals Inc. said it’s stopping work on a treatment for a rare eye disease because of a new US drug-pricing law with the potential to limit how much it could charge for the medication in the future.Alnylam will not begin a planned late-stage trial of its drug... + más
ALNY Reiterates Guidance, TVTX Loss Widens, DXCM Paints Rosy Outlook | RTTNews
Halted Stocks | Forbes
About iurex | Privacy Policy | Disclaimer |